- Conditions
- Breast Cancer
- Interventions
- high dose chemo then auto hematopoietic cell transplant
- Procedure
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 19 Years to 70 Years
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2005
- U.S. locations
- 1
- States / cities
- Stanford, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
- Interventions
- trastuzumab, gefitinib, laboratory biomarker analysis
- Biological · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
- Interventions
- recombinant vaccinia-MUC1 vaccine, recombinant vaccinia-TRICOM vaccine, laboratory biomarker analysis, quality-of-life assessment
- Biological · Other · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Glioblastoma, Melanoma Stage IV, Breast Cancer, Prostate Cancer, Glioblastoma Multiforme, GBM, Brain Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Prostate Cancer, Melanoma Recurrent, Prostate Cancer Metastatic, Recurrent Glioblastoma, Newly Diagnosed Glioblastoma
- Interventions
- ST101, Temozolomide, Radiation
- Drug · Radiation
- Lead sponsor
- Sapience Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 7
- States / cities
- San Francisco, California • Denver, Colorado • Warrenville, Illinois + 4 more
- Conditions
- Locally Advanced Breast Cancer, Metastatic (Stage IV) Breast Cancer, Stage III-IV Breast Cancer or Inflammatory
- Interventions
- Not listed
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 280 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2022
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Breast Cancer, Colorectal Cancer, Lung Cancer, Pancreatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- denileukin diftitox, recombinant fowlpox-CEA(6D)/TRICOM vaccine, therapeutic autologous dendritic cells
- Biological
- Lead sponsor
- H. Kim Lyerly
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia • Durham, North Carolina
- Conditions
- Breast Cancer
- Interventions
- doxorubicin hydrochloride, semaxanib, conventional surgery, radiation therapy, tamoxifen
- Drug · Procedure · Radiation
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2003
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Breast Cancer
- Interventions
- cyclophosphamide, methotrexate, sunitinib malate, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Breast Cancer
- Interventions
- paclitaxel, sorafenib tosylate, placebo
- Drug · Other
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2022
- U.S. locations
- 43
- States / cities
- Muscle Shoals, Alabama • Fayetteville, Arkansas • Anaheim, California + 39 more
- Conditions
- Breast Cancer
- Interventions
- filgrastim, docetaxel, vinorelbine
- Biological · Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2012
- U.S. locations
- 99
- States / cities
- Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 61 more
- Conditions
- Breast Cancer
- Interventions
- Alpelisib, Fulvestrant, Letrozole, Goserelin, Leuprolide
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 383 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 25
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Anaheim, California + 20 more
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Hormone Receptor Positive Breast Carcinoma, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8
- Interventions
- Computed Tomography, Fludeoxyglucose F-18, Positron Emission Tomography
- Procedure · Other
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 98
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 75 more
- Conditions
- Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
- Interventions
- vorinostat, trastuzumab
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Des Moines, Iowa • Sioux City, Iowa + 11 more
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma
- Interventions
- CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine, Chemotherapy, Computed Tomography, Computed Tomography Assisted Biopsy, Sargramostim, Ultrasound-Guided Biopsy, Biospecimen Collection, Positron Emission Tomography (PET)
- Biological · Drug · Procedure
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Breast Carcinoma, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8, Recurrent Breast Carcinoma
- Interventions
- Informational Intervention, Quality-of-Life Assessment, Survey Administration
- Other
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 174 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Breast Cancer
- Interventions
- monoclonal antibody HuHMFG1
- Biological
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Breast Cancer
- Interventions
- cyclophosphamide, docetaxel, doxorubicin hydrochloride
- Drug
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years to 69 Years · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Breast Cancer, Solid Tumors
- Interventions
- PF-07220060 + PF-07104091 combination dose escalation, PF-07104091 + PF-07220060 + fulvestrant dose expansion, PF-07104091 + PF-07220060 + letrozole dose expansion
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 192 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Santa Monica, California • Boston, Massachusetts + 5 more
- Conditions
- Fallopian Tube Cancer, Female Reproductive Cancer, Recurrent Breast Cancer, Recurrent Ovarian Epithelial Cancer, Stage III Ovarian Epithelial Cancer, Stage IV Breast Cancer, Stage IV Ovarian Epithelial Cancer
- Interventions
- ixabepilone, pegylated liposomal doxorubicin hydrochloride
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2014
- U.S. locations
- 5
- States / cities
- Farmington, Connecticut • Albany, New York • New York, New York + 1 more
- Conditions
- Breast Cancer
- Interventions
- HER-2/neu peptide vaccine
- Biological
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Breast Cancer
- Interventions
- Avastin, Gemcitabine, Abraxane
- Drug
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- HER2-negative Breast Cancer, Hormone-receptor-positive Breast Cancer, Metastatic Breast Cancer, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, HER2 Negative Breast Carcinoma, Hormone Receptor Positive Breast Carcinoma, Metastatic Breast Carcinoma
- Interventions
- Biospecimen Collection
- Procedure
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Male Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
- Interventions
- vorinostat, paclitaxel, bevacizumab
- Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Breast Carcinoma, Recurrent Breast Carcinoma, Stage IV Breast Cancer
- Interventions
- Bevacizumab, Carboplatin, Paclitaxel, Placebo, Trastuzumab
- Biological · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2015
- U.S. locations
- 373
- States / cities
- Jonesboro, Arkansas • Castro Valley, California • Emeryville, California + 236 more